BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 33490314)

  • 1. Hiding in plain sight: Gene panel and genetic markers reveal 26-year undiagnosed tumor-induced osteomalacia of the rib concurrently misdiagnosed as X-linked hypophosphatemia.
    Colazo JM; DeCorte JA; Gillaspie EA; Folpe AL; Dahir KM
    Bone Rep; 2021 Jun; 14():100744. PubMed ID: 33490314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-induced osteomalacia.
    Florenzano P; Gafni RI; Collins MT
    Bone Rep; 2017 Dec; 7():90-97. PubMed ID: 29021995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
    Arai R; Onodera T; Terkawi MA; Mitsuhashi T; Kondo E; Iwasaki N
    BMC Musculoskelet Disord; 2017 Feb; 18(1):79. PubMed ID: 28193220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-Induced Osteomalacia With Normal Fibroblast Growth Factor-23 (FGF23) and Idiopathic Hypercalciuria.
    Velazquez-Navarro JA; Loya-Teruel E; Rios-Gomez M; Montes-Ramirez JE
    Cureus; 2022 Jan; 14(1):e20893. PubMed ID: 35145798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphaturic mesenchymal tumor (PMT): exceptionally rare disease, yet crucial not to miss.
    Ghorbani-Aghbolaghi A; Darrow MA; Wang T
    Autops Case Rep; 2017; 7(3):32-37. PubMed ID: 29043208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
    Kinoshita Y; Fukumoto S
    Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-induced osteomalacia treated with T12 tumor resection.
    Mancini AJ; Sabet A; Nielsen GP; Parker JA; Schwab JH; Ward A; Wu JS; Malabanan AO
    Endocrinol Diabetes Metab Case Rep; 2022 Dec; 2022():. PubMed ID: 36511458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor-Induced Osteomalacia.
    Hartley IR; Roszko KL; Li X; Pozo K; Streit J; Del Rivero J; Magone MT; Smith MR; Vold R; Dambkowski CL; Collins MT; Gafni RI
    JBMR Plus; 2022 Aug; 6(8):e10661. PubMed ID: 35991529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphaturic mesenchymal tumor without osteomalacia: additional confirmation of the "nonphosphaturic" variant, with emphasis on the roles of FGF23 chromogenic in situ hybridization and FN1-FGFR1 fluorescence in situ hybridization.
    Sent-Doux KN; Mackinnon C; Lee JC; Folpe AL; Habeeb O
    Hum Pathol; 2018 Oct; 80():94-98. PubMed ID: 29514106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent phosphaturic mesenchymal tumor causing tumor-induced osteomalacia treated with image-guided ablation.
    Horng JC; Van Eperen E; Tutton S; Singh R; Shaker JL; Wooldridge AN
    Osteoporos Int; 2021 Sep; 32(9):1895-1898. PubMed ID: 33655402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic and molecular features of six cases of phosphaturic mesenchymal tumor.
    Sun L; Dehner C; Kenney J; McNulty SM; Zhu X; Pfeifer JD; Maluf HM; Chrisinger JSA
    Virchows Arch; 2021 Apr; 478(4):757-765. PubMed ID: 33151412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-induced osteomalacia in association with PTEN-negative Cowden syndrome.
    Berglund JA; Gafni RI; Wodajo F; Cowen EW; El-Maouche D; Chang R; Chen CC; Guthrie LC; Molinolo AA; Collins MT
    Osteoporos Int; 2018 Apr; 29(4):993-997. PubMed ID: 29380000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphaturic mesenchymal tumors: what an endocrinologist should know.
    Boland JM; Tebben PJ; Folpe AL
    J Endocrinol Invest; 2018 Oct; 41(10):1173-1184. PubMed ID: 29446010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An intracranial mass causing tumor-induced osteomalacia (TIO): Rapid and complete resolution of severe osteoporosis after surgical resection.
    Colazo JM; Thompson RC; Covington NV; Dahir KM
    Radiol Case Rep; 2020 May; 15(5):492-497. PubMed ID: 32140194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
    Weber TJ; Liu S; Indridason OS; Quarles LD
    J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: Novel NIPBL-BEND2 fusion gene identified in osteoblastoma-like phosphaturic mesenchymal tumor of the fibula.
    Sakai T; Okuno Y; Murakami N; Shimoyama Y; Imagama S; Nishida Y
    Front Oncol; 2022; 12():956472. PubMed ID: 36686800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatonins: From Discovery to Therapeutics.
    Kritmetapak K; Kumar R
    Endocr Pract; 2023 Jan; 29(1):69-79. PubMed ID: 36210014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphaturic Mesenchymal Tumor in the Proximal Femur Presenting as Tumor-induced Osteomalacia: A Case Report and Literature Review.
    Tungenwar S; Subith S; Mukadam M; Kokate S; Gunay S
    J Orthop Case Rep; 2024 Feb; 14(2):23-28. PubMed ID: 38420233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
    Fukumoto S
    J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-induced Osteomalacia: A Comprehensive Review.
    Minisola S; Fukumoto S; Xia W; Corsi A; Colangelo L; Scillitani A; Pepe J; Cipriani C; Thakker RV
    Endocr Rev; 2023 Mar; 44(2):323-353. PubMed ID: 36327295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.